Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €104.39 EUR
Change Today +0.222 / 0.21%
Volume 136.0
ICY On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 12:35 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

incyte corp (ICY) Snapshot

Open
€99.41
Previous Close
€104.17
Day High
€104.89
Day Low
€99.29
52 Week High
07/15/15 - €110.56
52 Week Low
10/13/14 - €34.70
Market Cap
18.8B
Average Volume 10 Days
235.1
EPS TTM
--
Shares Outstanding
180.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INCYTE CORP (ICY)

incyte corp (ICY) Related Businessweek News

No Related Businessweek News Found

incyte corp (ICY) Details

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, as well as INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer. The company’s product pipeline also comprises INCB52793, which is in Phase I/II clinical trial for the treatment of B-lymphoid malignancies; INCB50465 that is in Phase I/II clinical trial for hematology/oncology; and INCB39110+INCB40093, which is in Phase I/II trial for B-lymphoid malignancies. In addition, it is developing epacadostat that is in Phase II clinical trial for metastatic melanoma, as well as in Phase I/II trial for non-small cell lung cancer and various tumor types; and capmatinib, which is in Phase I/II clinical trial for the treatment of solid tumors, as well as in Phase II trial for hepatocellular carcinoma and non-small cell lung cancer. Further, the company is developing INCB54828 that is in Phase I/II clinical trial for the treatment of solid tumors; INCB54329, which is in Phase I/II clinical trial for the treatment of hematology/oncology; and baricitinib that is in Phase III trial for rheumatoid arthritis, as well as in Phase IIb clinical trial for psoriasis, and Phase II trial for diabetic nephropathy. It has a collaboration and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

588 Employees
Last Reported Date: 02/17/15
Founded in 1991

incyte corp (ICY) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $2.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $113.8K
Chief Drug Development Officer and Executive ...
Total Annual Compensation: $403.0K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $365.6K
Executive Vice President of Human Resources
Total Annual Compensation: $354.0K
Compensation as of Fiscal Year 2014.

incyte corp (ICY) Key Developments

Incyte Corporation Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for Fiscal 2015

Incyte Corporation reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. For the quarter, total revenues were $162,984,000 against $99,582,000 for the same period of last year. Loss from operations was $7,394,000 against $26,187,000 for the same period of last year. Profit before provision for income taxes was $9,430,000 against loss before provision for income taxes of $36,803,000 for the same period of last year. Net income was $9,294,000 against net loss of $36,873,000 for the same period of last year. Net income per basic and diluted share was $0.05 against net loss per share of $0.22 for the same period of last year. For the six months, total revenues were $322,260,000 against $189,374,000 for the same period of last year. Loss from operations was $14,326,000 against loss of $49,123,000 for the same period of last year. Loss before provision for income taxes was $8,560,000 against $70,711,000 for the same period of last year. Net loss was $9,063,000 against $70,830,000 for the same period of last year. Net loss per basic and diluted share was $0.05 against $0.43 for the same period of last year. The company now expects that 2015 net product revenues from Jakafi will be in the range of $560 million to $575 million, an increase from the previous range of $525 million to $565 million, driven by strong underlying demand.

Incyte Corporation to Report Q2, 2015 Results on Aug 04, 2015

Incyte Corporation announced that they will report Q2, 2015 results at 10:00 AM, US Eastern Standard Time on Aug 04, 2015

Incyte Corporation, Q2 2015 Earnings Call, Aug 04, 2015

Incyte Corporation, Q2 2015 Earnings Call, Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICY:GR €104.39 EUR +0.222

ICY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $60.58 USD +1.02
ARIAD Pharmaceuticals Inc $8.99 USD -0.45
BioMarin Pharmaceutical Inc $125.26 USD -3.98
Jazz Pharmaceuticals PLC $164.29 USD -4.53
Vertex Pharmaceuticals Inc $125.18 USD -2.34
View Industry Companies
 

Industry Analysis

ICY

Industry Average

Valuation ICY Industry Range
Price/Earnings 100.0x
Price/Sales 33.3x
Price/Book 391.7x
Price/Cash Flow 1,629.2x
TEV/Sales 31.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit www.incyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.